The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2014Restoring the Nigrostriatal Pathway with Living Micro-Tissue Engineered Axonal Tracts
Study Rationale:
By the time Parkinson’s disease (PD) symptoms appear, typically 60% of neurons in the substantia nigra and their axonal projections (nerve fibers) to the striatum... -
Rapid Response Innovation Awards, 2014Novel Mechanism for Death of Dopaminergic Neurons in a Model for Parkinson’s Disease
Study Rationale:
Parkinson’s disease (PD) is due in large part to the death of dopaminergic neurons in a part of the brain called the substantia nigra. An understanding of why, as we... -
Research Grant, 2014Novel Nicotinic Receptor Agonist for Treating Levodopa-induced Dyskinesia
Promising Outcomes of Original Grant:
Our initial hypothesis was two-fold: first, that specific nicotinic (chemical messenger) receptor subtypes are involved in nervous system responses to levodopa and... -
Research Grant, 2013Utility of a Novel Nicotinic Receptor Agonist for Treating Levodopa-induced Dyskinesia
Objective/Rationale:
It has been suggested that a nicotinic acetylcholine receptor (nAChR) agonists may restore the deficits caused by the loss of nicotinic acetylcholine subunits found in Parkinson’s... -
Therapeutic Pipeline Program, 2013Developing Disease-Modifying Therapies to Treat Parkinsons’s Disease by Enhancing the Clearance of Alpha Synuclein
Objective/Rationale:
This proposal seeks to develop a novel therapy that can slow the progression of Parkinson’s disease (PD) by optimizing chemical compounds that can decrease levels of alpha... -
Research Grant, 2013Continuous Subcutaneous Administration of Levodopa/Carbidopa (ND0612) for the Treatment of Parkinson's Disease
Objective/Rationale:
Improving consistency of plasma levodopa has been a longstanding pharmacological challenge. ND0612 is a proprietary formulation of levodopa and carbidopa continuously...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.